Resource

 

 

 

 

 

 

 

 

 

 

 

Banking & Finance - Capital Markets: Equity

Osborne Clarke advises Investec on £70 million placing for Blue Prism

30 Jan 2018

International legal practice Osborne Clarke has advised Investec Bank plc on the successful £70 million placing for AIM quoted Blue Prism Group plc, a global leader in robotic process automation.

The fundraising comprised a primary placing by Blue Prism to raise £40 million to accelerate its global growth and a secondary placing by certain selling shareholders to raise £30 million.

The Osborne Clarke team that advised on the transaction was led by Partner Jonathan King who was assisted by Senior Associate Ed Nisbet.

Osborne Clarke advises Investec on £70 million placing for Blue Prism

30 Jan 2018

International legal practice Osborne Clarke has advised Investec Bank plc on the successful £70 million placing for AIM quoted Blue Prism Group plc, a global leader in robotic process automation.

The fundraising comprised a primary placing by Blue Prism to raise £40 million to accelerate its global growth and a secondary placing by certain selling shareholders to raise £30 million.

The Osborne Clarke team that advised on the transaction was led by Partner Jonathan King who was assisted by Senior Associate Ed Nisbet.

WFW advises Saffron Energy on Italian oil & gas portfolio acquisitions and institutional cornerstone investment and placing to raise £14m

30 Jan 2018

Watson Farley & Williams (WFW) has advised AIM-traded Saffron Energy Plc (Saffron Energy) on its agreements to acquire the Italian oil & gas portfolios of each of Sound Energy Plc, listed on AIM (Sound Energy) and Po Valley Energy Ltd, listed on ASX (Po Valley).

Debevoise Advises Polyus Gold in its $250 Million Convertible Bonds Offering

29 Jan 2018

The Moscow and London offices of Debevoise & Plimpton LLP have advised the firm’s longstanding client PJSC Polyus (“Polyus”) on the issue by its indirect subsidiary Polyus Finance plc of $250 million senior bonds convertible into global depositary receipts representing ordinary shares of Polyus.

The bonds are guaranteed jointly and severally by Polyus and its subsidiary, JSC Polyus Krasnoyarsk, and were offered and sold outside the United States in reliance on Regulation S of the US Securities Act 1933, as amended.

Herbert Smith Freehills advises Sinopec Oilfield Service Corporation on US$572 million H-share placement

29 Jan 2018

Leading global law firm Herbert Smith Freehills has advised Sinopec Oilfield Service Corporation on its private placement of 3.3 billion H-shares on the Hong Kong Exchange.

The H-share placement was made to Sinopec Century Bright Capital Investment Limited and China Structural Reform Fund Corporation Limited, and was completed on 24 January after regulatory approvals were received. It injects close to US$572 million into one of the world' largest oilfield service companies.

Freshfields advises on Shanghai Pharma’s US$402m H-share placement in Hong Kong

29 Jan 2018

Freshfields Bruckhaus Deringer (‘Freshfields’) has advised Shanghai Pharmaceuticals Holding Co. Ltd. (‘Shanghai Pharma’) on its placement of approximately 153m new H-shares on the Hong Kong Stock Exchange. The transaction closed today (26 January 2018) and raised US$402m.

The placing shares represent around 5.7 per cent of the total existing issued share capital. Shanghai Pharma plans to use the proceeds of the placement to fund the development of its pharmaceutical manufacturing and distribution businesses and replenish its working capital.

Freshfields advises on Shanghai Pharma’s US$402m H-share placement in Hong Kong

29 Jan 2018

Freshfields Bruckhaus Deringer (‘Freshfields’) has advised Shanghai Pharmaceuticals Holding Co. Ltd. (‘Shanghai Pharma’) on its placement of approximately 153m new H-shares on the Hong Kong Stock Exchange. The transaction closed today (26 January 2018) and raised US$402m.

The placing shares represent around 5.7 per cent of the total existing issued share capital. Shanghai Pharma plans to use the proceeds of the placement to fund the development of its pharmaceutical manufacturing and distribution businesses and replenish its working capital.